

Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14-kDa group II phospholipase A₂

Makoto Murakami¹, Ichiro Kudo¹, Hideo Nakamura², Yuichi Yokoyama², Hiroshi Mori¹ and Keizo Inoue¹

¹*Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113, Japan* and ²*Research Laboratories, Dainippon Pharmaceutical Co. Ltd, Osaka 564, Japan*

Received 1 May 1990; revised version received 26 May 1990

Appreciable phospholipase A₂ activity was detected in a hind paw homogenate from rats with adjuvant arthritis or carrageenan-induced edema. The activity was neutralized by treatment with antibody raised against rat platelet secretory phospholipase A₂, indicating that 14-kDa group II phospholipase A₂ was induced in the hind paw during the process of inflammation. Injection of purified rat platelet phospholipase A₂ into the hind paw of rats with adjuvant-induced arthritis resulted in exacerbation of edema in a dose-dependent manner, whereas no effect was observed on either normal rats or animals with carrageenan-induced edema under the same experimental conditions. These results suggest the importance of mammalian group II phospholipase A₂ in the pathogenesis of some types of inflammation.

Phospholipase A₂; Adjuvant arthritis; Carrageenan-induced edema

1. INTRODUCTION

Phospholipase A₂ plays a central role in liberating free fatty acids and lysophospholipids from membrane phospholipids, thereby initiating the production of lipid mediators (eicosanoids, platelet activating factor, etc.) of the inflammatory process. Several studies have implicated extracellular phospholipases A₂ in the pathogenesis of disorders of the cardiovascular, gastrointestinal and pulmonary systems, skin and connective tissues [1]. Mammalian 14-kDa phospholipases A₂ have been classified into two groups based on their primary structure [2]. Group I enzymes exist mainly in digestive organs such as the pancreas [3,4], while group II enzymes are widely distributed in non-pancreatic tissues such as the spleen [5,6], liver [7], intestine [8] or platelets [9–11]. The group II enzymes have also been detected in exudated fluid at inflamed sites, such as glycogen-induced ascitic fluid in rabbits [12], casein-induced ascitic fluid in rats [13], or human synovial fluid in patients with rheumatoid arthritis [14–16]. It is therefore postulated that group II phospholipase A₂ may play some critical role in the process of inflammation.

This idea has been further supported by observations that inflammation was induced in animals by injection of phospholipases A₂ [12–21]. However, such induction of inflammation has not always been observed, and sometimes no appreciable change has been detected at sites where purified enzyme was injected.

When a rat receives an intradermal injection of complete Freund's adjuvant, chronic arthritis with remarkable paw edema develops, and this has been widely used as a model system for human rheumatoid arthritis. In the present study, we found that the level of phospholipase A₂ was greatly elevated under these pathological conditions. Also, we observed that injection of mammalian 14-kDa group II phospholipase A₂ purified from rat platelets exacerbated the paw edema in rats with adjuvant arthritis. It is suggested that some pathological conditions may be required in order for the enzyme to become active.

2. MATERIALS AND METHODS

2.1. Adjuvant arthritis

Male rats of the Sprague-Dawley (SD) strain, weighing 190–200 g (8 weeks old), were used. The adjuvant employed, a fine suspension of dry heat-killed *Mycobacterium butyricum* (Difco) in light mineral oil (Bayol F), was made up at a concentration of 10 mg/ml. Adjuvant arthritis was induced by an intradermal injection of 0.06 ml of adjuvant into the tail. Two weeks after the injection of adjuvant, rats showing medium to severe arthritis with remarkable edema (approximately 90% of total population) were selected and used [22].

2.2. Carrageenan-induced hind paw edema in rats

Male SD rats, weighing 100–130 g, were used. Hind paw edema was

Correspondence address: I. Kudo, Department of Health Chemistry, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113, Japan

Abbreviations: ELISA, enzyme-linked immunosorbent assay; EDTA, ethylenediamine tetraacetate; PBS, phosphate-buffered saline, SDA-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis

induced by subcutaneous injection of 0.1 ml of 1% carrageenan (Wako) solution into the right foot pad of rats [23].

2.3. Measurement of phospholipase A₂ activity in hind paw homogenates

Normal rats or those with inflammation were anesthetized with ether and killed. The hind paws of these rats were minced with scissors, suspended in 4 vol of 20 mM Tris-HCl (pH 7.4) containing 1 mM EDTA relative to wet tissue weight, and homogenized in a Polytron homogenizer (Kinematica). Phospholipase A₂ activity in the homogenates was measured using ¹⁴C-labelled phosphatidylserine as a substrate, as described previously [24].

2.4. Measurement of phospholipase A₂ content by sandwich ELISA

Group II phospholipase A₂ content in hind paw homogenates was determined by sandwich ELISA using solid-phase attached polyclonal antibody R377 and the soluble biotinylated monoclonal antibody MD7.1 as described previously [25]. Immunoaffinity-purified rat platelet phospholipase A₂ was used as a standard.

3. RESULTS

The homogenates of hind paw obtained from normal rats, or those with adjuvant-induced arthritis or carrageenan-induced edema were tested for phospholipase A₂ activity. Appreciable phospholipase A₂ activity was detected in homogenates prepared from hind paws with both arthritis and carrageenan-induced paw edema, whereas the level of enzyme activity in the same parts of normal rat was very low (Fig. 1). When the homogenates were incubated with anti-rat 14-kDa group II phospholipase A₂ antibody R377 [25], the phospholipase A₂ activity was markedly reduced (Table I). The content of group II phospholipase A₂ in the homogenates was determined immunochemically using a sandwich ELISA method developed previously (Table II). Approximately 1 µg of group II phospholipase A₂ was detected in the inflamed site of rat with adjuvant arthritis. The hind paw of rats with carrageenan-induced edema also contained a significantly high level of group II phospholipase A₂, although the content was relatively lower than that in adjuvant arthritis. It was thus concluded that mammalian 14-kDa group II phospholipase A₂ is induced in both types of inflammation.

We next examined the effect of exogenous group II phospholipase A₂ on the development of inflammation induced by either adjuvant-arthritis rats or rats with carrageenan-induced edema. To avoid the possibility that contaminating substances exerted biological effects, we used the purest preparation so far available, an immunoaffinity-purified rat platelet phospholipase A₂, which gave a single protein band on SDS-PAGE followed by silver staining [25]. Injection of the phospholipase A₂ into the hind paw of adjuvant-arthritis rats resulted in exacerbation of edema within 1 h in a dose-dependent manner (Table III). The maximum effect was observed at doses of over 2 µg of enzyme. The effect lasted for at least 3 h, then decreased gradually, and disappeared 24 h after injection of the




Fig. 1. Phospholipase A₂ activity in hind paw homogenates from normal rats (A), rats with adjuvant arthritis (B) and rats with carrageenan-induced edema (C) (n = 6). The procedure is described in section 2.

enzyme. On the other hand, no exacerbating effect was observed in either rats with carrageenan-induced edema or control rats even when 5 µg of phospholipase A₂ was injected (Tables IV and V).

Table I

Effect of anti-rat 14-kDa group II phospholipase A₂ antibody on phospholipase A₂ activity in rat hind paw homogenates

Sample	Treatment with R377	Phospholipase A ₂ activity (nmol) fatty acids released/min/ml
Normal	—	0.63 ± 0.20
	+	0.41 ± 0.70
Adjuvant arthritis	—	5.04 ± 0.56
	+	0.96 ± 0.14
Carrageenan-induced edema	—	3.45 ± 1.17
	+	0.70 ± 0.22

Samples were incubated with 25 µg of antibody R377 [25] for 1 h on ice. The aliquots were then examined for phospholipase A₂ activity.

Each value is an average (± SE) of 3 independent samples.

Table II

Content of 14-kDa group II phospholipase A₂ in hind paw homogenates determined by sandwich ELISA

Sample	n	Content of phospholipase A ₂ (average (ng) ± SE)
Normal	6	not detectable
Adjuvant arthritis	6	932.6 ± 691.2
Carrageenan-induced edema	6	136.8 ± 34.1

Content of phospholipase A₂ was determined as described previously [25].

Table III
Effect of 14-kDa group II phospholipase A₂ on adjuvant induced arthritis in rats

Dose of phospholipase A ₂ (μg/paw)	n	Hind paw swelling (average (%) ± SE)			
		1	3	6	24 h
0 (untreated control)	6	0.8 ± 1.8	4.3 ± 1.6	3.2 ± 1.3	6.2 ± 2.7
0 (vehicle control)	6	9.5 ± 2.0	10.6 ± 1.3	8.8 ± 1.2	4.2 ± 3.7
0.2	6	11.4 ± 4.3	11.7 ± 5.0	7.8 ± 4.3	-1.1 ± 1.8
1	6	15.2 ± 2.4	13.1 ± 2.4	9.5 ± 2.4	4.7 ± 1.1
2	6	18.4 ± 2.4*	17.0 ± 3.5	15.6 ± 3.2	8.7 ± 2.2
5	6	16.6 ± 2.2*	17.2 ± 1.9*	14.5 ± 1.6*	6.4 ± 3.4

Purified rat platelet phospholipase A₂ was diluted with phosphate-buffered saline (PBS; pH 6.5) containing 0.1% gelatin and injected into the hind paw of rats with adjuvant arthritis (0.1 ml/paw). Hind paw volume was measured at indicated times after the injection of the enzyme by the water displacement method [22,23].

* 0.01 < P < 0.05 significantly different from each vehicle group

Table IV
Effect of 14-kDa group II phospholipase A₂ on carrageenan-induced hind paw edema in rats

Dose of phospholipase A ₂ (μg/paw)	n	Hind paw swelling (average (%) ± SE)				
		1	2	3	4	5 h
0 (untreated control)	6	4.4 ± 1.0*	1.4 ± 0.8**	-0.6 ± 1.9*	-4.5 ± 2.1*	-8.3 ± 2.1*
0 (vehicle control)	6	8.3 ± 1.0	6.9 ± 0.6	6.3 ± 0.5	2.9 ± 0.7	-2.2 ± 1.2
2	6	7.1 ± 0.7	7.2 ± 0.8	5.5 ± 1.2	1.1 ± 1.3	-2.1 ± 1.3
5	6	6.2 ± 0.7	4.9 ± 0.8	3.1 ± 0.9**	-0.8 ± 1.2*	-5.8 ± 0.9

Two hours after injection of carrageenan, purified rat platelet phospholipase A₂ in PBS (pH 6.5) containing 0.1% gelatin was injected into the hind paw of rats with edema (0.1 ml/paw). Hind paw volume was measured as described in Table III.

* 0.01 < P < 0.05 and ** P < 0.01 significantly different from each vehicle control group

Table V
Effect of 14-kDa group II phospholipase A₂ on normal rats

Dose of phospholipase A ₂ (μg/paw)	n	Hind paw swelling (average (%) ± SE)				
		1	2	3	4	5 h
0 (untreated control)	6	1.9 ± 2.0**	0.4 ± 1.3**	-0.3 ± 1.0**	-3.7 ± 1.2**	-0.7 ± 1.3**
0 (vehicle control)	6	17.8 ± 2.4	14.4 ± 1.7	12.1 ± 1.5	6.4 ± 1.8	1.5 ± 0.6
5	6	15.2 ± 0.9	8.1 ± 1.4*	6.8 ± 1.5*	1.3 ± 1.4	-1.1 ± 1.4

Purified rat platelet phospholipase A₂ in PBS (pH 6.5) containing 0.1% gelatin was injected into the hind paw of normal rats (0.1 ml/paw). Hind paw volume was measured as described in Table III.

* 0.01 < P < 0.05 and ** P < 0.01 significantly different from each vehicle control group

4. DISCUSSION

Adjuvant arthritis in rats is characterized as a form of chronic inflammation mediated by cellular immunity [26], whereas carrageenan-induced edema is an acute inflammation showing predominant infiltration of neutrophils [27]. In the present study, we detected an elevated level of 14-kDa group II phospholipase A₂ activity at the inflamed sites in both experimental models, although the location of the phospholipase A₂ remains to be identified. The results were consistent with previous observations that 14-kDa group II phospholipase A₂ activity was detected in extra-articular tissues under various pathological conditions, which included experimental models of acute inflammation and human chronic inflammatory diseases

[12-16]. These observations, together with a recent report that a potent regulator of inflammation, interleukin-1, induced transcription of the gene for 14-kDa group II phospholipase A₂ [28], suggest the possible involvement of the enzyme in a wide variety of pathogenic reactions.

Purified rat group II phospholipase A₂ exacerbated the adjuvant arthritis following injection *in situ*. The effect was transient and induced at low doses of the enzyme. The lowest amount of purified enzyme required for an appreciable effect was 1 μg, which corresponds to about 20 units of the enzyme. Several investigators have previously pointed out the pathological activity of snake venom or pancreatic phospholipases A₂ when administered exogenously. However, the amounts of these exocrine enzymes used were extraordinarily high

[17–20]; Pruzanski et al. showed that inflammatory effects of snake venom or pancreatic phospholipase A₂ were induced by injection of 60 000 units of enzyme [17]. The amount of the enzyme we used in the present study was within the range of activity detected in the hind paw homogenates of rats with experimental inflammation. Exogenously administered 14-kDa group II phospholipase A₂ produced a dose-dependent effect. The endogenous 14-kDa group II phospholipase A₂ would in fact exacerbate adjuvant arthritis after secretion into the extracellular space under certain conditions. The precise mechanism by which 14-kDa group II phospholipase A₂ exacerbates the inflammatory process is now under investigation.

No appreciable inflammatory response was detected when 14-kDa group II phospholipase A₂ was injected into the hind paw of normal rats. These findings were contradictory to previous reports of others.

Vishwanath et al. have shown that phospholipase A₂ partially purified from human rheumatoid synovial fluid induced edema when injected into mouse foot pads [21]. Phospholipase A₂ released from rabbit peritoneal exudate cells induced hyperemia subsequent to intradermal injection [19]. The discrepancy between the previous findings and the present data might be due to differences in sensitivity of the species employed. Alternatively, since only partially purified enzyme was used in previous studies, such preparations might have contained additional component(s) that affected the activity of the 14-kDa group II phospholipase A₂ and potentiated the induction of some pathological responses. In fact, one such component, a bacterial permeability increasing protein, has already been characterized by Elsbach et al. [29].

It is noteworthy that no exacerbating effect was observed in rats with carrageenan-induced edema when the animals were injected with 5 µg (100 units) of the phospholipase A₂. The difference in the effects of exogenous phospholipase A₂ on adjuvant arthritis and carrageenan-induced edema cannot be explained at present. The major cellular component in carrageenan-induced edema is neutrophils, whereas that in adjuvant arthritis is mononuclear cells such as T lymphocytes or macrophages. Some cells accompanying with arthritis might therefore release factor(s) essential for expression of the pathological effects of mammalian 14-kDa group II phospholipase A₂.

Acknowledgement: This work was supported in part by Grants-in-aid for Scientific Research (Nos. 63480490 and 01304049) from the Ministry of Education, Science and Culture of Japan.

REFERENCES

- [1] Vadas, P. and Pruzanski, W. (1986) *Lab. Invest.* 4, 391–404.
- [2] Heinrikson, R.L., Krueger, E.T. and Keim, P.S. (1977) *J. Biol. Chem.* 252, 4913–4921.
- [3] Ohara, O., Tamaki, M., Nakamura, E., Tsuruta, Y., Fujii, Y., Shin, M., Teraoka, H. and Okamoto, M. (1986) *J. Biochem.* 99, 733–739.
- [4] Sakata, T., Nakamura, E., Tsuruta, Y., Tamaki, M., Teraoka, H., Tojo, H., Ono, T. and Okamoto, M. (1989) *Biochim. Biophys. Acta* 1007, 124–126.
- [5] Ono, T., Tojo, H., Kuramitsu, S., Kagamiyama, H. and Okamoto, M. (1988) *J. Biol. Chem.* 263, 5732–5738.
- [6] Kanda, A., Ono, T., Yoshida, N., Tojo, H. and Okamoto, M. (1989) *Biochem. Biophys. Res. Commun.* 163, 42–48.
- [7] Aarsman, A.J., De Jong, J.G.N., Arnoldussen, E., Neys, F.W., Van Wassenaar, P.D. and Van Den Bosch, H. (1989) *J. Biol. Chem.* 264, 10008–10014.
- [8] Verger, R., Farrato, F., Mansbach, C. and Pieroni, G. (1982) *Biochemistry* 21, 6883–6889.
- [9] Hayakawa, M., Kudo, I., Tomita, M., Nojima, S. and Inoue, K. (1988) *J. Biochem.* 104, 767–772.
- [10] Mizushima, H., Kudo, I., Horigome, K., Murakami, M., Hayakawa, M., Kim, D.K., Kondo, E., Tomita, M. and Inoue, K. (1989) *J. Biochem.* 105, 520–525.
- [11] Komada, M., Kudo, I., Mizushima, M., Kitamura, N. and Inoue, E. (1989) *J. Biochem.* 106, 545–547.
- [12] Forst, S., Weiss, J., Elsbach, P., Maraganore, J.M., Reardon, L. and Heinrikson, R.L. (1986) *Biochemistry* 25, 8381–8385.
- [13] Chang, H.W., Kudo, I., Tomita, M. and Inoue, K. (1987) *J. Biochem.* 102, 147–154.
- [14] Hara, S., Kudo, I., Chang, H.W., Matsuta, K., Miyamoto, Y. and Inoue, K. (1989) *J. Biochem.* 105, 395–399.
- [15] Seelhamer, J.J., Pruzanski, W., Vadas, P., Plant, S., Miller, J.A., Kloss, J. and Johnson, L.K. (1989) *J. Biol. Chem.* 264, 5335–5338.
- [16] Kramer, R.M., Hession, C., Johansen, B., Hayes, G., McGray, P., Chow, E.P., Tizard, R. and Pepinsky, R.B. (1989) *J. Biol. Chem.* 264, 5768–5775.
- [17] Pruzanski, W., Vadas, P. and Fornasier, V. (1986) *J. Clin. Dermatol.* 86, 380–383.
- [18] Vadas, P. and Hay, J.B. (1983) *Can. J. Physiol. Pharmacol.* 61, 561–566.
- [19] Vadas, P., Wasi, S., Movat, H.Z. and Hay, J.B. (1981) *Nature* 293, 583–585.
- [20] Cirino, G., Peers, S.H., Wallace, J.L. and Flower, R.J. (1989) *Eur. J. Pharmacol.* 166, 505–510.
- [21] Vishwanath, B.S., Fawzy, A.A. and Franson, R.C. (1988) *Inflammation* 12, 549–561.
- [22] Nakamura, H. and Shimizu, M. (1979) *J. Pharmacol. Exp. Ther.* 211, 20–25.
- [23] Nakamura, H., Yokoyama, Y., Motoyoshi, S., Ishii, K., Imazu, C., Seto, Y., Kadokawa, T. and Shimizu, M. (1983) *Arzheim. Forsch. Drug Res.* 33, 1555–1569.
- [24] Horigome, K., Hayakawa, M., Inoue, K. and Nojima, S. (1987) *J. Biochem.* 101, 625–631.
- [25] Murakami, M., Kudo, I., Natori, Y. and Inoue, K. (1990) *Biochim. Biophys. Acta* 1043, 34–42.
- [26] Billingham, M.E.J. (1983) *Pharmacol. Ther.* 21, 389–428.
- [27] Rosa, M.D. (1972) *J. Pharm. Pharmacol.* 24, 89–102.
- [28] Nakano, T., Ohara, O., Teraoka, H. and Arita, H. (1990) *FEBS Lett.* 261, 171–174.
- [29] Elsbach, P. and Weiss, J. (1988) *Biochim. Biophys. Acta* 947, 29–52.